2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-125047
    Daledalin tosylate 23226-37-1 98%
    Daledalin tosylate is an orally active indoline antidepressant targeting noradrenaline and serotonin transporters in the brain. Daledalin tosylate enhances central monoaminergic neurotransmission to alleviate depressive symptoms. Daledalin tosylate is proming for rasearch of depression, including endogenous and neurotic depression.
    Daledalin tosylate
  • HY-12515B
    (S)-Nicardipine 76093-36-2 99.25%
    (S)-Nicardipine ((S)-YC-93 free base) is the less active S enantiomer of Nicardipine. Nicardipine is a calcium channel blocker with an IC50 of 1 μM for blocking cardiac calcium channels. Nicardipine acts as an agent for chronic stable angina and for controlling blood pressure.
    (S)-Nicardipine
  • HY-12515C
    (R)-Nicardipine 76093-35-1 99.64%
    (R)-Nicardipine ((R)-YC-93 free base) is the less active R enantiomer of Nicardipine. Nicardipine (YC-93) is a calcium channel blocker with an IC50 of 1 μM for blocking cardiac calcium channels. Nicardipine acts as an agent for chronic stable angina and for controlling blood pressure.
    (R)-Nicardipine
  • HY-12520B
    (R)-SKF 38393 hydrochloride 81702-42-3 98%
    (R)-SKF 38393 ((±)-SKF-38393) hydrochloride is a potent and selective D1 dopamine receptor antagonist. (R)-SKF 38393 hydrochloride inhibits G protein-coupled inwardly rectifying potassium (GIRK) channel.
    (R)-SKF 38393 hydrochloride
  • HY-125296
    Fipronil sulfone 120068-36-2 99.75%
    Fipronil sulfone is the major metabolite of Fipronil.Fipronil sulfone selectively inhibits GABA receptor with IC50 of 175 nM (assayed by displacement of 4′-ethynyl-4-n-[2,3-3H2]- propylbicycloorthobenzoate ([3H]EBOB) from the noncompetitive blocker site).
    Fipronil sulfone
  • HY-12542R
    Dantrolene (Standard) 7261-97-4
    Dantrolene (Standard) is the analytical standard of Dantrolene. This product is intended for research and analytical applications. Dantrolene is an orally active, non-competitive glutathione reductase inhibitor with a Ki of 111.6 μM and an IC50 of 52.3 μM. Dantrolene is a ryanodine receptor (RyR) antagonist and Ca2+ signaling stabilizer. Dantrolene is a direct-acting skeletal muscle relaxant. Dantrolene can be used for the research of muscle spasticity, malignant hyperthermia, Huntington's disease and other neuroleptic malignant syndrome.
    Dantrolene (Standard)
  • HY-12542S
    Dantrolene-13C3 1185234-99-4 ≥99.0%
    Dantrolene-13C3 is the 13C3 labeled Dantrolene. Dantrolene (F368), a muscle relaxant, non-competitively inhibits human erythrocyte glutathione reductase. Ki and IC50 values are 111.6 μM and 52.3 μM, respectively. Dantrolene is a ryanodine receptor antagonist and Ca2+ signaling stabilizer. Dantrolene can be used for the research of muscle spasticity, malignant hyperthermia, Huntington's disease and other neuroleptic malignant syndrome.
    Dantrolene-13C3
  • HY-125555
    Azosulfamide 133-60-8 98%
    Azosulfamide has an anticonvulsant effect and can be used for research of epilepsy. Azosulfamide is active against recurrent tetanus.
    Azosulfamide
  • HY-125558
    PT150 189035-07-2 98%
    PT150 (ORG-34517) is a competitive and orally active glucocorticoid receptor antagonist. PT150 shows neuroprotective effects. PT150 has the potential for the research of Parkinson’s disease.
    PT150
  • HY-125603
    Termitomycamide B 1254277-89-8 98%
    Termitomycamide B (compound 2) is a neuroprotective agent that can be obtained from Termitomyces titanicus. Termitomycamide B effectively inhibits endoplasmic reticulum stress-dependent cell death. Termitomycamide B can be used in the study of neurodegenerative diseases.
    Termitomycamide B
  • HY-125673
    AC-178335 212966-15-9 98%
    AC-178335 is a SRIF antagonist, with a Ki of 172 nM. AC-178335 blocks SRIF inhibition of adenylate cyclase in vitro (IC50=5.1 μM). AC-178335 induces GH release in anesthetized rats.
    AC-178335
  • HY-125692
    L-740093 154967-59-6 98%
    L-740093 is a potent cholecystokinin-B receptor antagonist. L-740093 has excellent central nervous system (CNS) penetration.
    L-740093
  • HY-125693
    L685818 143839-74-1 98%
    L685818 is a specific immunophilin ligand. L685818 was neuroregenerative and non-neuroprotective in primary brain cultures. L685818 protects dopaminergic neurons from toxic inhibition of MPP+ and 6-OHDA, reduces tyrosine hydroxylase (TH) loss, and promotes neuronal process regeneration. L685818 is also an antifungal reagent for Cryptococcus neoformans.
    L685818
  • HY-125738
    Obscurolide A1 144397-99-9 98%
    Obscurolide A1 is a Phosphodiesterase (PDE) inhibitor (IC50=8 mM) that can be obtained from Streptomyces viridochromogenes culture. Obscurolide A1 has the potential to study neurological and inflammatory diseases.
    Obscurolide A1
  • HY-125743
    S-1 Methanandamide 157182-50-8 ≥98.0%
    S-1 Methanandamide ((S)-Methanandamide), an Anandamide analog, is a CB1 receptor ligand with a Ki of 173 nM. S-1 Methanandamide inhibits electrically-evoked twitch response in mouse vas deferens with an IC50 value of 230 nM.
    S-1 Methanandamide
  • HY-126061
    1,7-Dimethyluric acid 33868-03-0 99.82%
    1,7-Dimethyluric acid is the metabolite of caffeine.
    1,7-Dimethyluric acid
  • HY-126123
    NR2B-selective NMDA receptor antagonist 1 457897-92-6 98%
    NR2B-selective NMDA receptor antagonist 1 (compound 29) is a potent antagonist of NR1/NR2B receptors, with IC50s of 0.05 μM, 0.73 μM, 2.4 μM to NR1/NR2B NMDA receptor, hERG, α1-AdR, respectivity. NR2B-selective NMDA receptor antagonist 1 exhibites efficient permeability across the blood–brain barrier.
    NR2B-selective NMDA receptor antagonist 1
  • HY-126125
    CHIR-98023 252916-76-0 98%
    CHIR-98023 is a potent, selective and reversible inhibitor of GSK3, with IC50s of 10 nM and 6.7 nM for GSK3α and GSK3β, respectively. CHIR-98023 can improve insulin action and glucose metabolism.
    CHIR-98023
  • HY-126158
    SRI-29574 1928712-46-2 98%
    SRI-29574 is an allosteric modulator of the dopamine transporter (DAT). SRI-29574 partially inhibits the uptake of the DAT (IC50=2.3 nM) and also partially inhibits the uptake of the serotonin transporter (SERT) and norepinephrine transporter (NET). SRI-29574 may serve as a useful probe to study the function and regulatory mechanisms of DAT.
    SRI-29574
  • HY-126175
    Neostigmine iodide 1212-37-9 98%
    Neostigmine iodide is a reversible acetylcholinesterase inhibitor with muscle tone-enhancing activity. Neostigmine iodide is primarily used to improve muscle function in patients with myasthenia gravis. Neostigmine iodide is also used in routine anesthesia to reverse the effects of nondepolarizing muscle relaxants such as rocuronium.
    Neostigmine iodide
Cat. No. Product Name / Synonyms Application Reactivity